Abstract：
The safety and efficacy of sabatolimab, a novel immunotherapy targeting T-cell immunoglobulin domain and mucin domain-3 (TIM-3), was assessed in combination with hypomethylating agents (HMAs) in patients with HMA-naive revised International Prognostic System Score (IPSS-R) high- or very high-risk myelodysplastic syndromes (HR/vHR-MDS) or chronic myelomonocytic leukemia (CMML). Sabatolimab + HMA had a safety profile similar to that reported for HMA alone and demonstrated durable clinical responses in patients with HR/vHR-MDS. These results support the ongoing evaluation of sabatolimab-based combination therapy in MDS, CMML, and acute myeloid leukemia.
摘要：
sabatolimab的安全性和有效性，一种针对T细胞免疫球蛋白域和粘蛋白域3（TIM-3）的新型免疫疗法，在未经HMA修订的国际预后系统评分（IPSS-R）高或极高危骨髓增生异常综合征（HR/vHR-MDS）或慢性粒单核细胞白血病（CMML）的患者中，与低甲基化药物（HMA）联合进行评估。Sabatolimab+HMA的安全性与单独的HMA相似，并在HR/vHR-MDS患者中表现出持久的临床反应。这些结果支持对基于sabatolimab的联合治疗在MDS中的持续评估，CMML,和急性髓细胞性白血病.
